The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
作者信息
Petty R D
机构信息
Ninewells Hospital and Medical School, Dundee, UK.
出版信息
Clin Oncol (R Coll Radiol). 1996;8(3):186-9.
PMID:8814375
Abstract
摘要
相似文献
1
2
[Oncogenes and suppressor genes in the genesis and progression of solid tumors in children].
Pediatr Med Chir. 1994 May-Jun;16(3):203-9.
3
Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.
Mol Carcinog. 1999 May;25(1):30-41.
4
Comparable oncogene and tumor suppressor gene alterations in rat and human osteosarcomas.
Prog Clin Biol Res. 1992;376:321-30.
5
[Contribution of molecular and genetic biology in oncology].
Rev Med Brux. 1995 May-Jun;16(3):102, 105-12.
6
[Tumor suppressor p53 gene: a potential target for cancer therapy?].
Bull Cancer. 1997 Jul;84(7):753-6.
7
[Current problems in development of new anticancer agents for new molecular targets].
Gan To Kagaku Ryoho. 1996 Jan;23(2):211-8.
8
[Oncogenes and tumor suppressor genes: general features].
Acta Otorhinolaryngol Ital. 1996 Jun;16(3 Suppl 54):17-20.
9
Molecular interrelationships in multidrug resistance (review).
Anticancer Res. 1994 Mar-Apr;14(2A):433-5.
10
The same gene can be tumour suppressing and tumour promoting.
Med Hypotheses. 2008;70(5):1066. doi: 10.1016/j.mehy.2007.11.009. Epub 2008 Jan 3.
Zotero 插件